A multicenter evaluation of MIC distributions for ECV definition to detect

[1]  C. Lass‐Flörl,et al.  New Insight into Amphotericin B Resistance in Aspergillus terreus , 2013, Antimicrobial Agents and Chemotherapy.

[2]  A. Simon,et al.  Forty-one recent cases of invasive zygomycosis from a global clinical registry. , 2009, The Journal of antimicrobial chemotherapy.

[3]  Russell E. Lewis,et al.  Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species , 2011, Clinical Microbiology Reviews.

[4]  F. Barchiesi,et al.  In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. , 2010, The Journal of antimicrobial chemotherapy.

[5]  A. Espinel-Ingroff,et al.  Antifungal Resistance: Cellular and Molecular Mechanisms , 2010 .

[6]  K. Kwon-Chung.  Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  L. Pagano,et al.  Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Ghannoum,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) , 2011, Antimicrobial Agents and Chemotherapy.

[9]  G. Hasçelik,et al.  Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. , 2008, Medical mycology.

[10]  J. Guarro,et al.  In Vitro and In Vivo Activities of Posaconazole and Amphotericin B in a Murine Invasive Infection by Mucor circinelloides: Poor Efficacy of Posaconazole , 2012, Antimicrobial Agents and Chemotherapy.

[11]  J. Guarro,et al.  Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated Infection , 2009, Antimicrobial Agents and Chemotherapy.

[12]  J. Guarro,et al.  Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and Voriconazole , 2014, Antimicrobial Agents and Chemotherapy.

[13]  J. Rex,et al.  Amphotericin B: time for a new "gold standard". , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Meis,et al.  Apophysomyces elegans: Epidemiology, Amplified Fragment Length Polymorphism Typing, and In Vitro Antifungal Susceptibility Pattern , 2010, Journal of Clinical Microbiology.

[15]  G. Jensen,et al.  Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis , 2010, Antimicrobial Agents and Chemotherapy.

[16]  G Kahlmeter,et al.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  John Turnidge,et al.  Statistical Methods for Establishing Quality Control Ranges for Antibacterial Agents in Clinical and Laboratory Standards Institute Susceptibility Testing , 2007, Antimicrobial Agents and Chemotherapy.

[18]  D. Loebenberg,et al.  In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model , 2002, Antimicrobial Agents and Chemotherapy.

[19]  M. Cuenca‐Estrella,et al.  EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing , 2013, Current Fungal Infection Reports.

[20]  John Turnidge,et al.  Setting and Revising Antibacterial Susceptibility Breakpoints , 2007, Clinical Microbiology Reviews.

[21]  M. Wrzosek,et al.  DNA barcoding in Mucorales: an inventory of biodiversity , 2013, Persoonia.

[22]  P. Ambrose,et al.  A Long Journey from Minimum Inhibitory Concentration Testing to Clinically Predictive Breakpoints: Deterministic and Probabilistic Approaches in Deriving Breakpoints , 2009, Infection.

[23]  L. Pagano,et al.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  J. Guarro,et al.  Efficacy of posaconazole in a murine model of disseminated infection caused by Apophysomyces variabilis. , 2012, The Journal of antimicrobial chemotherapy.

[25]  T. Sorrell,et al.  Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer? , 2015, Pathology.

[26]  E. Mellado,et al.  In vitro activity of antifungals against Zygomycetes. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[27]  M. Vehreschild,et al.  Mucormycosis treated with posaconazole: review of 96 case reports , 2013, Critical reviews in microbiology.

[28]  G. Petrikkos,et al.  Epidemiology of mucormycosis in Europe. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  F. Dromer,et al.  Agents of Systemic and Subcutaneous Mucormycosis and Entomophthoromycosis , 2011 .

[30]  M. Cuenca‐Estrella,et al.  Activity of Posaconazole and Other Antifungal Agents against Mucorales Strains Identified by Sequencing of Internal Transcribed Spacers , 2009, Antimicrobial Agents and Chemotherapy.

[31]  J. Meis,et al.  Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales , 2011, Journal of Clinical Microbiology.

[32]  J. Guarro,et al.  Correlation between InVitro Activity of Posaconazole and InVivo Efficacy against Rhizopus oryzae Infection in Mice , 2010, Antimicrobial Agents and Chemotherapy.

[33]  D. Kontoyiannis,et al.  Erratum: Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases (Clinical Infectious Diseases (April 1, 2006) 42 (e61-e65)) , 2006 .